Subcellular compartmentalization of docking protein-1 contributes to progression in colorectal cancer  by Friedrich, Teresa et al.
EBioMedicine 8 (2016) 159–172
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comSubcellular compartmentalization of docking protein-1 contributes to
progression in colorectal cancerTeresa Friedrich a,1, Michaela Söhn a,1, Tobias Gutting a,1, Klaus-Peter Janssen b, Hans-Michael Behrens c,
Christoph Röcken c, Matthias P.A. Ebert a, Elke Burgermeister a,⁎
a Dept. of Medicine II, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
b Dept. of Surgery, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
c Institute of Pathology, Christian-Albrechts University, Kiel, GermanyAbbreviations: a-C, anti-C-terminal; a-N, anti-N-termi
CCLE, cancer cell line encyclopedia; CDK, cyclin-dependen
cytoplasm; DBD, DNA-binding domain; DC, C-terminal (p
docking protein-1; EGF, epidermal growth factor; ER, en
embedded; FL, full-length; FOS, FBJ murine osteosarcom
hematoxylin eosin; HRP, horse radish peroxidase; HYB,
ligand-binding domain; M, distant metastasis; MAPK, mi
nodal spread; NC, normal colon tissue; NES, nuclear exp
plextrin homology; PLA, proximity ligation assay; PPARγ,
tumor classiﬁcation system; PY, phospho-tyrosine; R, rela
tyrosine kinase; RXR, retinoid X receptor; SI, small intesti
factor; TMA, tissue microarray; TSS, tumor-speciﬁc surviv
⁎ Corresponding author at: Department of Medicine
Mannheim, Germany.
E-mail address: elke.burgermeister@medma.uni-heide
1 Equal author contribution.
http://dx.doi.org/10.1016/j.ebiom.2016.05.003
2352-3964/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 4 January 2016
Received in revised form 19 April 2016
Accepted 4 May 2016
Available online 5 May 2016Full-length (FL) docking protein-1 (DOK1) is an adapter protein which inhibits growth factor and immune re-
sponse pathways in normal tissues, but is frequently lost in human cancers. Small DOK1 variants remain in
cells of solid tumors and leukemias, albeit, their functions are elusive. To assess the so far unknown role of
DOK1 in colorectal cancer (CRC),we generatedDOK1mutantswhichmimic the domain structure and subcellular
distribution of DOK1 protein variants in leukemia patients. We found that cytoplasmic DOK1 activated peroxi-
some-proliferator-activated-receptor-gamma (PPARγ) resulting in inhibition of the c-FOS promoter and cell pro-
liferation, whereas nuclear DOK1 was inactive. PPARγ-agonist increased expression of endogenous DOK1 and
interaction with PPARγ. Forward translation of this cell-based signaling model predicted compartmentalization
of DOK1 in patients. In a large series of CRC patients, loss of DOK1 protein was associated with poor prognosis at
early tumor stages (*p= 0.001; n = 1492). In tumors with cytoplasmic expression of DOK1, survival was im-
proved, whereas nuclear localization of DOK1 correlated with poor outcome, indicating that compartmentaliza-
tion of DOK1 is critical for CRC progression. Thus, DOK1 was identiﬁed as a prognostic factor for non-metastatic
CRC, and, via its drugability by PPARγ-agonist, may constitute a potential target for future cancer treatments.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Docking protein
DOK
RAS
PPAR
Colorectal cancer1. Introduction
Adapter and scaffold proteins rewire signaling networks by subcel-
lular compartmentalization and enable spatio-temporal adaptation to
environmental cues that may be derailed in disease conditions like can-
cer (Good et al., 2011). Docking protein-1 (DOK1) is a versatile adapter
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. This is an open access article underDOK1 belongs to a protein family which controls immune receptors in
lymphocytes and myeloid cells and inhibits inﬂammation in vivo
(Shinohara et al., 2005). Dok1-deﬁcient mice suffer from hematopoietic
defects (Yasuda et al., 2004) and, together with loss of other DOKmem-
bers, succumb to aggressive sarcomas (Mashima et al., 2010). DOK1 in-
hibits cytosolic (CTK) or receptor (RTK) tyrosine kinases and binds p120
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signaling cascades in non-hematopoietic cells (Songyang et al., 2001;
Shinohara et al., 2004; Zhao et al., 2006). DOK1 sensitizes human cancer
cells to apoptosis by etoposide, emphasizing its role in tumor suppres-
sion (Siouda et al., 2012).
Alternative translation initiation yields several protein isoforms
encoded by the same DOK1mRNA (Kobayashi et al., 2009). Full-length
(FL) p62 DOK1 has an N-terminal plextrin homology (PH) domain for
membrane binding, a phospho-tyrosine-binding (PTB) domain for in-
teraction with phospho-tyrosine substrates (e.g. growth factor recep-
tors, integrins, etc. (Oxley et al., 2008)) and a C-terminal domain with
proline and phospho-tyrosine residues which bind SH3-domains and
SRC kinase, respectively. The C-terminal part of DOK1 also interacts
with p120RASGAP, SH2 (Songyang et al., 2001; Shinohara et al., 2004)
and other PTB domains (e.g. hakai (Mukherjee et al., 2012)) and con-
tains a nuclear export signal (NES) (Niu et al., 2006) that mediates
nucleo-cytoplasmic shuttling of DOK1. FL p62 DOK1 localizes to the nu-
cleus in starved or suspended cells, to the plasmamembrane and the cy-
tosol in growth factor-stimulated and adherent cells, consistent with
tyrosine kinase inhibition atmembranes (Niu et al., 2006). N-terminally
truncated DOK1 (p37–44) lacks the PH-domain, locates to the
perinuclear area and may be responsible for transport between cytosol
and nucleus (Kobayashi et al., 2009). Small DOK1 (p19–22) is deﬁcient
of both the PTB and the C-terminal domains (Hubert et al., 2000). Poly-
morphisms and frame shift mutations in human leukemias (Lee et al.,
2004; Lee et al., 2007) introduce aberrant stop codons that yield C-ter-
minally deleted DOK1 (p33–35) isoforms with a nuclear localisation
signal (NLS) which are conﬁned to the nucleus as well. Splice variants
or dominant-negative mutants were also described for other DOK fam-
ily members (Hosooka et al., 2001; Baldwin et al., 2007; Hamuro et al.,
2008). However, the function of subcellular compartmentalization of
DOK mutants remains unknown.
Loss of FL p62 DOK1 as a tumor suppressor is a common event in
human cancers, including solid tumors (Berger et al., 2010; Saulnier et
al., 2012). Oncogenic kinases (Janas and Van Aelst, 2011; Miah et al.,
2014) and viruses (Siouda et al., 2014) facilitate proteasomal degrada-
tion of DOK1 and epigenetic silencing of the DOK1 gene. In contrast,
agents that promote stress responses (such as E2F) (Siouda et al.,
2012) and differentiation, e.g. ligands for peroxisome proliferator-acti-
vated receptor-gamma (PPARγ) (Hosooka et al., 2008; Burgermeister
et al., 2011), up-regulate DOK1 expression. DOK1 counteracts inactiva-
tion of PPARγ by the RAS-ERK1/2 pathway in human cells (Demers et
al., 2009; Burgermeister et al., 2011) and mice (Hosooka et al., 2008;
Jiang et al., 2015).
DOK1 also triggers apoptosis by recruiting and interacting with
SMADs (Yamakawa et al., 2002) and inhibits expression of inﬂammato-
ry genes driven by NFκB and STATs (Nold-Petry et al., 2015) in hemato-
poietic cells. Genomic alterations of SMAD3, P53, RAS, and APC are
hallmarks of colorectal cancer (CRC) (Kodach et al., 2008).We therefore
hypothesized that transcription factors are down-stream effectors of
DOK1 mutants in human cancer cells, where FL p62 DOK1 is lost.
We demonstrate here that DOK1 activated the ligand-dependent
transcriptional activity of PPARγ and inhibited activation of the
human c-FOS promoter downstream of RAS, resulting in reduced cell
proliferation. This anti-tumor mechanism was allocated to protein do-
mains and subcellular compartmentalization of DOK1 protein variants.
Collectively, our patient data propose DOK1 as a prognostic factor and
potential drugable target for human CRC.
2. Materials and methods
2.1. Patients
Tissue specimens of primary CRC caseswere obtained from 1648 pa-
tients who had undergone elective surgery for CRC at the University
Hospital Kiel (1995–2009). Inclusion criteria and clinico-pathologicalcharacteristics of the study population are summarized in (Ingold
Heppner et al., 2014). For histology, formalin-ﬁxed [in 10% neutralized
formalin] and parafﬁn-embedded (FFPE) tissue samples were stained
using hematoxylin and eosin (HE). Tumors were classiﬁed according
to theWHO classiﬁcation, and the pTNM stage was determined accord-
ing to the seventh edition of the UICC guidelines. FFPE tissue samples
were used to generate custom-made tissue microarrays (TMAs) as de-
scribed (Kononen et al., 1998). Fresh-frozen patient tissue specimens
from the University Hospital Munich comprising matched CRC tumor
(TU), adjacent normal colon (NC) and livermetastases (M)were graded
by histopathological evaluation (stages II–IV) on HE-stained cryosec-
tions. Mutations of KRASG12, KRASG13 and BRAFV600E were evaluated
by high resolution melting (Ebert et al., 2012). The study was approved
by the Ethics Committees of theUniversities of Kiel, Heidelberg andMu-
nich, Germany. Commercial TMAs (Co483) were purchased from US
Biomax, Rockville, MD, USA.
2.2. Animals
Studies on wild-type (WT) (C57BL6J, Charles River, Wilmington,
MA) were approved (Az35-9185.82-G-176-12) by the government of
Baden-Württemberg, Karlsruhe, Germany.
2.3. Reagents
Chemicals were fromMerck (Darmstadt) or Sigma (Steinheim, Ger-
many), rosiglitazone (rosi, #71740) from Cayman (Ann Arbor, MI). Abs
were GFP (#11814460001, Roche, Mannheim, Germany), FLAG (F7425,
Sigma), DOK1 (M-19, sc-6277; A3, sc-6929), PPARγ (sc-7273; sc-7196),
CAV1 (sc-894), HSP90 (sc-7947), lamin AC (sc-20681) (all from Santa
Cruz Biotech., CA), phospho-S82(84) PPARγ (AW504, UpstateMillipore,
Schwalbach, Germany), DOK1 (ab8112), POM121 (ab190015, both
from Abcam, Cambridge, UK), calnexin (#2433), PPARγ (#2435),
ERK1/2 (#4370) (all from Cell Signaling, Danvers, MA), pan-RAS
(#R1198-01D, US Biological, Biomol, Hamburg, Germany), villin
(#3722, Epitomics, Burlingame, CA). DOK1 siRNA and control were
from Dharmacon (Thermoﬁsher Scientiﬁc, Waltham, MA).
2.4. DNA-constructs
Serum-response element (SRE) plasmid was from Stratagene
(Agilent, Santa Clara, CA). 3xPPRE-pTK-luc, GFP-PPARγ and PPARγ1-
mutant H7 with deletion in helix 7 of the ligand-binding domain
(LBD) were mentioned before (Burgermeister et al., 2011). PPARγ1-
mutant Dbox (Zechel et al., 1994) was generated by deletion of
149DLNCRIHKKSRN160 in the DNA-binding domain (DBD), point mu-
tant S84A by replacement of serine with alanine in the MAPK motif
83ASPPYYSEKT92 in the AF1 of PPARγ1 (P37231-2) (Diradourian et
al., 2005). Human FL DOK1 (start codon MDGAV, aa 1–481, 62 kDa,
NM_001381.3) (Songyang et al., 2001), N-terminal truncation mutant
DN (start codon MDGAV, aa 1–280, 33 kDa) (Lee et al., 2004; Lee et
al., 2007) and C-terminal truncation mutant DC (start codon MLENS,
aa 140–481, 44 kDa) (Kobayashi et al., 2009) were ampliﬁed by PCR
from cDNA of SW480 cells and inserted with or without N-terminal
FLAG-tag into pTarget (Promega GmbH, Mannheim, Germany). FL
and DC point DOK1 (Q99704) mutants NES (348LLKAKL353 to
348AAKAKA353) and RA (R207A, R208A, R222A, R223A) were gen-
erated as detailed by the manufacturer (Quickchange, Stratagene).
2.5. Cell culture and assays
Human embryonic kidney (HEK293T), colorectal (CRC) (SW480,
HCT116, HT29, Caco2) and gastric (GC) (AGS, MKN45) cancer cell
lines (American Type Culture Collection, Rockville, MD) were main-
tained as recommended by the distributor. Transfection and luciferase
assays were described elsewhere (Burgermeister et al., 2007). The 3-
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proliferation assay was conducted according to the manufacturer
(Roche Diagnostics).
2.6. Cell fractionation, coimmunoprecipitation (CoIP), GST-pulldown,
Western blot
The methods were performed as described (Burgermeister et al.,
2007). Kits for RAS GTPase pulldown assays were from Biocat (Heidel-
berg, Germany).
2.7. Immunoﬂuorescence microscopy
Staining and image acquisitionwas done as before (Burgermeister et
al., 2011). Proximity ligation assay (PLA)was performed as described by
the manufacturer (Duolink, Olink Bioscience, Uppsala, Sweden). Auto-
matic counting of ﬂuorescence signals (n N 50 per ﬁeld , n = 5 ﬁelds
per image) from Abs and DAPI was conducted with Image J (imagej.
nih.gov/ij).
2.8. Immunohistochemistry (IHC)
Ab and HE stainings were done as published (Ebert et al., 2012).
In brief, antigen retrieval was performed by heating of
deparafﬁnized sections in citrate buffer (10 mM citric acid pH 6.0,
0.05% (v/v) Tween 20, H-3300) and incubated with H2O2 Block and
Ultra V Block (both Thermo Scientiﬁc, Braunschweig, Germany) to
avoid unspeciﬁc reactions. Rabbit polyclonal DOK1 (ab8112) Ab
was diluted 1:800. For visualization, the ImmPRESS-HRP-Universal-
Antibody Polymer and the NovaRED substrate kit (both from
VectorLabs, Peterborough, UK) were applied. Mouse monoclonal
DOK1 (A3) Abwas diluted 1:200, and staining was processed accord-
ing to the protocol from Vectastain ABC (HRP) kit (Vectorlabs). For
detection, the substrate 3,3′-diamino benzidine (brown color) was
used (Vectorlabs). Counterstaining was done with hematoxylin
(Dr. K. Hollborn & Söhne GmbH & Co KG; Leipzig, Germany). The fre-
quency and intensity of DOK1 positivity was analysed in custom-
made (n = 1648 CRC patients, from CR, Kiel (Ingold Heppner et al.,
2014)) and commercial (n = 40 CRC patients, n = 8 normal human
colon, CO483, US Biomax) TMAs (Boger et al., 2015; Metzger et al.,
2016). The staining scores were deﬁned as follows: 0+ = negative
(0–25%), 1+ = weak (25–50%), 2+ = moderate (50–75%), 3+ =
strong (75–100% positive rate compared to total cell number per
ﬁeld). In tumor and stroma cells, nuclear, perinuclear and cytoplas-
mic stainings were evaluated. Signals from Abs were quantiﬁed
manually and rater-blinded at a standard bright-ﬁeld microscope
using Image J (imagej.nih.gov/ij) (n N 50 per ﬁeld ; n = 5 ﬁelds per
image).
2.9. Reverse transcription PCR (RT-PCR) and quantitative PCR (qPCR)
Assayswere performed as published (Ebert et al., 2012). Primers and
probes for RT-qPCR from the Universal Probe Library (UPL) system
(Roche Diagnostics) are listed in Table S1.
2.10. Software tools and statistics
The statistical evaluation of IHC data from patients' TMAs was per-
formed using SPSS version 20.0 (IBM Corporation, Armonk, NY) as de-
tailed in (Boger et al., 2015; Metzger et al., 2016). The cut-off values
for dichotome analysis of staining scores (0 to 3+) were calculated as
≥2.0 for tumor and ≥0.6 for stroma positivity. Univariate and multivar-
iate analyses followed by logistic Cox regression were conducted to
identify signiﬁcant differences between patient groups using log-rank
and Fisher exact tests. Data from in vitro studies are means ± S.E.
from at least 3 independent experiments from different cell passagesor individuals (frozen samples from mice or patients). Optical densities
(OD) of bands in gels from Western blots (Fusion Solo, VWR, Radnor,
Pennsylvania) and PCRs (GelIX Imager, INTAS, Göttingen, Germany)
were collected using automated imaging devices and quantiﬁed with
Image J (imagej.nih.gov/ij). Data were normalized to house keeping
genes (B2M, B2m) or proteins (HSP90, laminAC, β-actin) and calculated
as -fold or % compared to control. Statistical analysis was done with
Graphpad Prism (version 4.0, La Jolla, CA). All tests were unpaired and
two-sided if not stated otherwise. P-values b 0.05 were considered sig-
niﬁcant (*). Signaling pathways were depicted with CellDesigner (ver-
sion 4.2, systems-biology.org). Bioinformatic data were retrieved from
cbioportal.org according to the TCGA publication guidelines (Cerami et
al., 2012; Gao et al., 2013).
3. Results
3.1. Expression of DOK1 protein variants in cells and tissues
For validation of DOK1 antibodies, we selected four human CRC
(SW480, HCT116, HT29, Caco2) and one non-cancer (HEK293T)
cell line which differ in their KRAS and BRAF mutation status
(Jhawer et al., 2008). Consistent with previous results in seven
human gastric cancer (GC) (Burgermeister et al., 2011) and pancre-
atic cancer (PANC1) cells (Kobayashi et al., 2009), Western blots
(Fig. 1A) of total cell lysates (TCLs) using an Ab against the N-termi-
nal (A3) half of the protein (covering the PH and PTB domains)
(Shinohara et al., 2004; Hosooka et al., 2008) detected a predomi-
nant DOK1 protein of 37 kDa.
Abs which recognized the C-terminus (M19 (van Dijk et al., 2000),
ab8112 (Siouda et al., 2014)) of FL p62 DOK1 revealed a band of
44 kDa size. FL p62 DOK1 and the 19–22 kDa variants (Hubert et
al., 2000) were not found in any of the cell lines. In contrast, FL p62
DOK1 was present together with smaller isoforms in whole tissue ly-
sates from tumor (TU) and matched normal colon (NC) samples of
CRC patients and intestinal organs of C57BL6J mice (Fig. 1B). Thus,
DOK1 protein variants could be distinguished by domain-selective
Abs (Fig. 1C) in CRC cells and tissues similar to human leukemias
(Lee et al., 2004, 2007).
3.2. N- and C-terminal domains determine subcellular localization of DOK1
We then elucidated whether DOK1 variants are subjected to sub-
cellular compartmentalization in human CRC cells as observed in
leukemias. To this end, immunoﬂuorescence microscopy was per-
formed in SW480 and HCT116 cells (Fig. 2A). Anti-N Ab visualized
a constitutive DOK1 signal in the nucleus, anti-C Ab a steady-state
cytoplasmatic and perinuclear distribution of DOK1. Rapid transloca-
tions upon stimulation (such as serum or EGF e.a.) were not ob-
served (not shown). Subcellular fractionation (Fig. 2B) conﬁrmed
that anti-N Ab detected p37 DOK1 enriched in the nucleus (NUC)
(by 3 to 6-fold) compared with the cytoplasm (CYT) and the insolu-
ble (INS) fraction in HEK293T and CRC cell lines (SW480, HCT116,
HT29, Caco2). There was no colocalization between nuclear pore
components (POM121) and DOK1 detected by either Ab. Instead, a
partial overlap between calnexin, a marker for the endoplasmic re-
ticulum (ER), and perinuclear DOK1 staining was observed (Fig.
2C) (Niu et al., 2006; Kobayashi et al., 2009). In frozen samples
from mouse and human NC tissues, anti-C Ab again recognized cyto-
solic and insoluble p44 and p62 DOK1 but only low levels in the nu-
cleus (Fig. 2D). Thus, C-terminal epitopes were correlated with
cytoplasmic, N-terminal ones with nuclear distribution of DOK1 var-
iants. The distribution was different in normal vs.malignant cells, ev-
ident in loss of insoluble and cytoplasmic vs. gain of nuclear DOK1.
To mimic the modular structure of the endogenous DOK1 variants
and to understand their functional domains, we generated expression
plasmids for p33 DN (PH+, PTB+, NES−) (Lee et al., 2004, 2007) and
Fig. 1. Expression of DOK1 protein in CRC cells and tissues. (A) Top: Detection of DOK1 variants in human transformed and CRC cell lines (1 = SW480, 2 = HCT116, 3 = HT29, 4 =
HEK293T, 5 = Caco2) using domain-speciﬁc antibodies (Abs). Total cell lysates (TCLs) were subjected to Western blotting with anti-N (A3) or anti-C (M19) DOK1 Abs. Bottom: O.D.
values of bands in gels were normalized to HSP90 and calculated as -fold ± S.E. vs. normal colon (NC) tissue (n = 3 per cell line, *p b 0.05 vs. NC, Kruskal Wallis test). NC control is
the mean of n = 5 healthy individuals. (B) DOK1 variants in intestinal tissues. Top: Whole tissue lysates from frozen samples of matched tumor (TU) and normal colon (NC)
specimens from CRC patients (or C57BL6J mice as control) were analysed as in A. Bottom: Quantitative data are -fold ± S.E. (n = 15 cases, *p b 0.05 vs. p62, two-way ANOVA). (C)
Scheme of human DOK1 protein variants. Legend: FL = full-length p62 DOK1, DC = p44 C-terminal part of DOK1 (Kobayashi et al., 2009), DN = p33–37 N-terminal part of DOK1,
DEL = small p19–22 deletion variant of DOK1 (Hubert et al., 2000), C = C-terminus, N = N-terminus, BCCL13 = leukemia variant (Lee et al., 2004, 2007). Subcellular localization and
Ab binding epitopes are depicted.
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Fig.1C). Immunoﬂuorescence stainings with FLAG-Ab visualized both
DOK1 truncation mutants upon transfection into HEK293T cells (Fig.
3A). Due to absence of theNES (Lee et al., 2004, 2007), DNwas enriched
in the nucleus, whereas DC, because of its functional NES (Kobayashi etal., 2009), remained in the cytosol. Anti-C Ab detected FL p62 DOK1 and
DC but not DN, while anti-N Ab (FLAG) recognized both mutants (Fig.
3B). Subcellular fractionation conﬁrmed that the N-terminal part of
DOK1 goes to the nucleus, whereas the C-terminal half stays in the
cytoplasm.
Fig. 2. Subcellular localization of DOK1 protein variants. (A) Anti-N Ab (a-N) recognizes nuclear DOK1, anti-C Ab (a-C) cytoplasmic DOK1. Cycling cells were ﬁxed and stained for
immunoﬂuorescence microscopy. Data show enrichment of DOK1 signals detected by a-N Ab in the nucleus (NUC) as -fold ± S.E. compared to a-C Ab (n= 3 per cell line, N 30 nuclei
per ﬁeld, n = 5 ﬁelds, *p b 0.05 a-N vs. a-C; Mann Whitney test). Colors: green = DOK1, blue = nuclei; Magniﬁcation 630×. (B) Anti-N Ab detects p37 DOK1 in the nucleus of
malignant cells. Cells were subjected to subcellular fractionation and Western blotting. O.D. values from bands in gels are means ± S.E. of DOK1 protein per fraction (n = 3 per cell
line, *p b 0.05 vs. NUC; Kruskal Wallis test). Legend: CYT = cytoplasm, NUC = nucleus, INS = insoluble membrane and matrix fraction (cytoskeleton, chromatin e.a.). (C) Anti-C Ab
detects colocalization of cytoplasmic DOK1 with calnexin (ER marker) but not with POM121 (ENV marker) in the perinuclear area of the endoplasmic reticulum (ER) and the nuclear
envelope (ENV). Anti-N Ab detects overlay of nuclear DOK1 with nuclei (DAPI). HEK293T cells were analysed as in A. Colors: green = organelle marker, red = DOK1, blue = nuclei;
Magniﬁcation 630×. (D) Anti-C Ab detects FL p62 and p44 DOK1 in the cytoplasm and insoluble fraction of non-malignant cells. Fresh-frozen normal colon (NC) tissue from patients
or C57BL6J mice was subjected to fractionation as in B. Results are shown as in B (n= 3 per species, *p b 0.05 vs. NUC, Kruskal Wallis test).
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Fig. 3. N- and C-terminal domains determine subcellular localizations of DOK1. (A) Ectopic DOK1mutants mimic compartmentalization of endogenous DOK1 protein variants. HEK293T
cells were transfected with expression plasmids encoding FL p62 DOK1 or the FLAG-tagged truncation mutants p33 DN and p44 DC for 48 h before immunoﬂuorescence staining using
FLAG Ab. Colors: green = FLAG-DOK1, blue = nuclei; Magniﬁcation 630×. Data show enrichment of DN in the nucleus (NUC) as -fold ± S.E. compared to DC (n= 3 per mutant, N 50
nuclei per ﬁeld, n = 5 ﬁelds, *p b 0.05 DN vs. DC, Mann Whitney test). (B) DN is targeted to the nucleus, DC to the cytoplasm. HEK293T cells were transfected as in A. TCLs were
subjected to subcellular fractionation and Western blotting using anti-N (FLAG) and anti-C DOK1 Abs. O.D. values normalized to HSP90 or lamin AC are -fold ± S.E. of DOK1 protein
per fraction (n= 3, *p b 0.05 mutant vs. FL, Kruskal Wallis test).
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As an exemplary target of DOK1, we studied the localization and ac-
tivity of PPARγ, a transcription factor downstream of and inhibited by
the RAS-ERK1/2 cascade (Burgermeister et al., 2007; Banks et al.,
2015). HEK293T cells were transfected with DOK1 truncation mutants
for 48 h followed by immunoﬂuorescence staining with PPARγ Ab
(#2435). In cycling cells transfected with empty vector (EV), endoge-
nous PPARγ signals were mainly cytosolic in the perinuclear area. DN
(NES−) evoked an enrichment of PPARγ in the nucleus (by 2 to 3 -
fold vs. EV), and subcellular fractionation conﬁrmed this observation
(S1). FL (NES+) and DC (NES+) had no effect on PPARγ distribution
(not shown). Thus, N-terminal domains confer nuclear, C-terminal do-
mains cytoplasmatic localization of PPARγ. To identify peptide motifs
responsible for DOK1 and PPARγ distributions, two additional point
mutants were generated in FL p62 DOK1. The nuclear export signal
(NES3 according to (Niu et al., 2006)) was deleted (“NES”) and argi-
nines R207–R208 and R222–R223, essential for interaction of the PTB
domain with phospho-tyrosine substrates (Oxley et al., 2008), were
mutated to alanine (“RA”). NES (NES−) evoked an accumulation of
PPARγ in the nucleus (by 2 to 3-fold vs. EV) (S1), whereas FL (NES+)
and RA (NES+) had no effect (not shown). Hence, only NES-deﬁcient
(NES−) DOK1 mutants forced PPARγ into the nucleus. Similar results
were obtained for HCT116 and SW480 cells (not shown). Thus, the
PTB core and the NES harbour amino acid residues important for spatial
control of PPARγ.
3.4. DOK1 forms a complex with PPARγ
To decide whether the effect of DOK1mutants on the localization of
PPARγ is mediated by interaction, coimmunoprecipitation (CoIP) of
whole tissue lysates from frozen samples of CRCpatientswas performed(Fig. 4A). Immunoprecipitation (“IP”)was donewith PPARγAb (H-100)
and immunoblot (“IB”) with anti-C DOK1 Ab. Endogenous FL p62 DOK1
was coprecipitated both in TU and NC samples. The interaction was
stronger (2.5-fold NC vs. TU) in non-malignant tissue than in CRC, con-
sistent with loss of FL p62 DOK1 in transformed cells. To visualize bind-
ing complexes, HEK293T cells were incubated for 16 h with vehicle
(DMSO) or the PPARγ-agonist rosiglitazone (rosi, 10 μM), and proxim-
ity ligation assay (PLA) was performed using anti-N DOK1 and PPARγ
(#2435) Abs (Fig. 4B). Colocalization was increased in the cytoplasm
upon ligand treatment (by 7-fold vs. DMSO) and appeared as pink
dots. No colocalization was seen in control stainings using only one Ab
in the PLA reaction. Thus, there is a constitutive interaction of endoge-
nous DOK1 with PPARγ which can be enhanced by PPARγ-agonist. In-
teractions between small DOK1 variants and PPARγ in human cancer
cell lines (AGS, MKN45, SW480, HCT116, HT29) were weak (not
shown), indicative of a loss of complex formation upon transformation.
To map the interaction sites on DOK1 and PPARγ, binding of mutant
proteins was quantiﬁed in CoIPs. HEK293T cells were transfected with
FLAG-DN or -DC together with GFP-PPARγ. IP was performed with
GFP Ab and IB with FLAG Ab and vice versa (S2). DC and DN were both
sufﬁcient for interaction with PPARγ. To identify counterpart binding
sites on both proteins, two bona ﬁde dockingmotifs in PPARγwere test-
ed as candidates, the S84A point mutant, which prevents phosphoryla-
tion of the receptor by MAPKs (Adams et al., 1997), and the Dbox
deletion mutant that abrogates heterodimerization with RXR and
DNA-binding of PPARγ (Zechel et al., 1994). The GFP-PPARγ-S84A and
-Dboxmutantswere cotransfectedwithDC-WT, -RA and -NES plasmids.
S84A bound stronger to DOK1 thanWT. However, dual combinations of
mutants, such as S84 and DC-RA or Dbox and DC-NES, fully abolished
the interaction. Thus, the tested pairs of peptide motifs (PTBDOK1-
S84PPARγ; NESDOK1-DboxPPARγ) contribute to the interaction of the two
proteins (see model in S2).
Fig. 4. DOK1 forms a complex with and increases transcriptional activity of PPARγ. (A) CoIP of FL p62 DOK1 and PPARγ from whole tissue lysates of matched frozen human TU and NC
specimens. Proteins were immunoprecipitated (“IP”) with PPARγ (H100) or no Ab (bead control). Coprecipitated proteins were detected (“IB”) with anti-N DOK1 Ab. Results are
means ± S.E. (n = 3 patients, *p b 0.05 NC vs. TU, two-way ANOVA). (B) Proximity ligation assay (PLA). HEK293T cells were serum-deprived for 16 h followed by incubation with
rosi (at 10 μM) or vehicle (DMSO) for 24 h. Immunoﬂuorescence stainings were done with anti-N DOK1 and PPARγ (#2435) Abs or single Ab (negative control). Results are -fold ±
S.E. (n= 3 per treatment, N 50 nuclei per ﬁeld, n= 5 ﬁelds, *p b 0.05 vs. rosi, Kruskal Wallis test). Colors: pink dots = DOK1–PPARγ colocalization, green = actin (phalloidin or “no
dye” negative control), blue = nuclei; Magniﬁcation 630× and 400×. (C) DOK1 promotes transcriptional activity of PPARγ. HCT116 cells were cotransfected with DOK1 and PPRE
reporter plasmids for 24 h followed by treatment with 1 μM rosi for 24 h. Luciferase activity in TCLs normalized to protein content was calculated as -fold ± S.E. (n = 3, *p b 0.05
DOK1 + rosi vs. EV + rosi, Kruskal Wallis test). PTB and C-terminal domains, but not the N-terminal part of DOK1, are required for PPARγ activation. (D) DOK1 increases PPARγ-target
gene expression. Cells were transfected and treated as above. Normalized CT-values from RT-qPCRs are -fold ± S.E. (n = 3, *p b 0.05 rosi vs. vehicle, Friedmann test). (E) DOK1
knock-down decreases PPARγ-activity. Cells were cotransfected with PPRE reporter plasmid and siRNA (at 100 nM) for 24 h and treated with 1 μM rosi for additional 24 h. Data are
shown as in C (n= 3 per cell line, *p b 0.05 DOK1- vs. control-siRNA; two-way ANOVA). (F) DOK1 knock-down reduces PPARγ-target gene expression. Cells were treated as in E and
data are presented as in D (n= 3, *p b 0.05 DOK1- vs. control-siRNA, Friedmann test).
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To determine if DOK1 also alters the activity of PPARγ, HCT116 cells
were transfected with DOK1 and a PPARγ-responsive (PPRE) reporter
plasmid followed by a 48 h treatment with rosi (1 μM) (Fig. 4C). Lucifer-
ase activity assays showed that FL p62 DOK1 and NES increased ligand-
dependent transcription (to 150 and 130% vs. EV). RAwas unresponsive,consistent with the observation that an intact PTB domain was required
for interactionwith and activation of PPARγ. DC stimulated transcription
(to 140%), whereas DN was inert. Similar results were obtained from
HEK293T cells, whereas SW480 cells were resistant, presumably due to
strong RAS activity caused by mutated KRASG12V alleles that lead to cy-
tosolic retention and inactivation of PPARγ by MEK1 and ERK1/2
(Diradourian et al., 2005; Burgermeister et al., 2007).
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CoA oxidase (ACO) conﬁrmed up-regulation of PPARγ-target genes by
DOK1 (Fig. 4D). Again, the C-terminal part of DOK1 with a functional
PTB was required for ligand-dependent activation of PPARγ. In line
with previous results from HEK293T and MKN45 cells (Burgermeister
et al., 2011), transient knock-down of endogenous DOK1 by siRNA in
HCT116 and SW480 cells decreased ligand-dependent PPARγ activation
(by 20 to 50% vs. control-siRNA) (Fig. 4E). Reduction of TFF3 and ACO
mRNA levels upon DOK1 knock-down (Fig. 4F) further corroborated
the positive regulation of PPARγ-target genes by DOK1.
3.6. DOK1 inhibits transcription from the c-FOS promoter
We next asked whether the effects of DOK1 on transcription are
independent from or coexisting with inhibition of the RAS-ERK1/2Fig. 5. DOK1 inhibits c-FOS promoter transcription. (A) Western blots of pulldown assays detec
RALGDS-GST as a bait. Results are -fold± S.E. (n=3 per cell line, *p b 0.05 vs. beads, KruskalW
DOK1 for 48 h before pulldown. Data are presented as in A (n = 3, n.s., two-way ANOVA). (
transfected with DOK1 plasmids for 24 h, serum deprived for 16 h and restimulated with EG
(n= 3 per cell line, n.s., two-way ANOVA). (D) DOK1 inhibits the human c-FOS promoter. HC
incubation with EGF (10 ng/ml) in serum-free medium for additional 24 h. Luciferase activity
EV, two-way ANOVA).pathway. RAS-pulldown assays were performed in TCLs from cycling
cells (Fig. 5A) or upon transfection of FL p62 DOK1 (Fig. 5B). Higher
pan-RAS activity was seen in KRASG12V mutant SW480 than in
KRASG13D mutant HCT116 cells. KRAS-WT cells (HEK293T, Caco2,
HT29) were negative. Consistent with others (Songyang et al.,
2001), DOK1 did not inhibit the activity of mutant RAS. Western
blot analyses corroborated that DOK1 was also unable to reduce
phosphorylation of ERK1/2 in starved cells that had been restimulat-
ed with EGF (10 ng/ml) for 0–30 min (Fig. 5C). As a genomic readout
for DOK1-mediated inhibition of the RAS-ERK1/2 cascade (Yoshida
et al., 2000), we measured transcriptional activation of the serum-
response element (SRE) in the human c-FOS promoter (Buchwalter
et al., 2004) (Fig. 5D). HCT116 cells were cotransfected with DOK1
and SRE reporter plasmids for 24 h, followed by serum deprivation
for 16 h and stimulation with EGF (10 ng/ml) for additional 24 h.ting active GTP-bound pan-RAS proteins in TCLs compared to total pan-RAS (input) using
allis test). (B) DOK1 does not inhibit mutant RAS. Cells were transfected with EV or FL p62
C) DOK1 does not inhibit ERK1/2 phosphorylation. HEK293T, SW480 and HCT116 were
F (10 ng/ml) for the times indicated. Data from Western blots of TCLs are shown as in A
T116 cells were cotransfected with DOK1 and SRE reporter plasmids for 24 h followed by
in TCLs normalized to protein content was calculated as -fold ± S.E. (n= 3, * p b 0.05 vs.
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by 62% and upon EGF-stimulation by 49% comparedwith EV controls.
Likewise, NES exerted an inhibition by 59% (53%) and RA by 61%
(52%). Thus, FL p62 DOK1 is an inhibitor of nuclear SRE-driven tran-
scription but not of upstream RAS-ERK1/2 signaling. DC was inert
compared with a robust inhibition of DN by 34% (38%).
Thus, deletion of the PH domain but not point mutations in the PTB
or NES reduced the ability of DOK1 to inhibit the SRE. Similar results
were obtained from HEK293T cells, whereas SW480 cells were again
unresponsive (not shown). Hence, theN-terminal part of DOK1was suf-
ﬁcient for inhibition of the c-FOS promoter, the C-terminal part neces-
sary for activation of PPARγ (Table S2).
3.7. DOK1 sensitizes cells to PPARγ-ligand-driven growth inhibition
To test if regulation of transcription by DOK1 translates into a de-
crease of cell growth, HEK293T cells were transfected with DOK1 plas-
mids and cultivated for 3 days followed by MTT proliferation assay.
Consistently (Ling et al., 2005; Zhao et al., 2006), DOK1 did not change
the basal proliferation rate compared with EV controls (data not
shown). Instead, FL p62 DOK1 enhanced growth inhibition exerted byFig. 6. DOK1 augments PPARγ-ligand-mediated inhibition of cell proliferation. (A) PTB and C-t
HCT116were transfectedwith DOK1plasmids, and proliferationwasmeasured after 5 days in p
0.05 DOK1+ rosi vs. EV+ rosi; two-way ANOVA). (B) DOK1 knock-down enhances cell growth
0.05 DOK1- vs. control-siRNA, two-way ANOVA). (C) Growth inhibition is PPARγ-receptor depe
Data are shown as in A (n= 3, *p b 0.05 vs.WT, one-way ANOVA).PPARγ-ligand (3 μM rosi for 3 days) to 80 ± 7% vs. EV (Fig. 6A). NES
but not RA was as efﬁcient as FL p62 DOK1 to augment the growth in-
hibitory response to rosi (82 ± 5%). DC also slowed cell growth
(84 ± 2%), DN did not. Similar results were obtained from HCT116
cells, whereas SW480 cells were resistant (not shown). Thus, the C-ter-
minal part of DOK1with a functional PTBdomain is necessary for PPARγ
activation and growth inhibition.
In contrast, DOK1-siRNA reduced the sensitivity of human GC
(Burgermeister et al., 2011) and CRC cells to PPARγ-ligand-mediated
growth inhibition. Proliferation was enhanced (by 23% SW480; 42%
AGS) compared to control-siRNA (Fig. 6B). Similar results were collect-
ed from HCT116, HT29 and MKN45 cells (not shown).
To distinguish ligand- from receptor-mediated effects, HEK293T
cells were transfected with GFP-PPARγ plasmids, and cell growth was
determined after 3 days in absence of ligand (Fig. 6C). Cells which re-
ceived S84A or Dbox mutants grew faster than those with WT-PPARγ
(131% and 116% vs. WT). The H7 mutant, with a deletion of helix 7 in
the LBD that renders PPARγ insensitive to ligands, increased growth to
124% vs. WT. Thus, the proposed DOK1 interaction sites on PPARγ
(S84 and Dbox) support the intrinsic anti-proliferative activity of
PPARγ even in absence of exogenous ligand.erminal domains, but not the N-terminal part of DOK1, are required for growth inhibition.
resence of rosi (3 μM). O.D. values fromMTT assayswere calculated as %±S.E. (n=3, *p b
. Cells were transfectedwith siRNA, and proliferation was determined as in A (n=3, *p b
ndent. HEK293T cells were transfected with PPARγ plasmids for 72 h in absence of ligand.
Fig. 7. Compartmentalization of DOK1 predicts prognosis of CRC patients. (A) Immunohistochemistry (IHC)with DOK1 anti-C Ab (ab8112) on tissuemicroarrays (TMAs) with tumor (TU,
n=1648) specimens from CRC patients. Representative images are shown. DOK1 (brown color)was localized to the tumor cells in the cytoplasm (i), the apical perinuclear area (ii) or the
nucleus (iii). Note the mixed pattern of DOK1 staining (positive control) in the normal colon glands both in epithelial (enterocytes) and stromal cells of the lamina propria (iv). DOK1
positivity was lost in a subset of tumors (v) and was absent in the secondary Ab only (negative control) staining (vi). Magniﬁcations 200×. (B) Loss of DOK1 protein expression
predicts poor survival in CRC patients. Kaplan–Meier curves of patient overall survival (OS). Upper panels: OS for DOK1 tumor and stroma expression; Lower panels: OS for nuclear
and cytoplasmic DOK1 expression in the tumor. Nuclear localization of DOK1 correlates with poor, cytoplasmic DOK1 with improved prognosis. Data are surviving proportions vs.
months (n= 1492 ,*p b 0.05 log-rank tests). Values for tumor-speciﬁc survival (TSS) and median survival are presented in Table S4.
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169T. Friedrich et al. / EBioMedicine 8 (2016) 159–1723.8. Subcellular compartmentalization of DOK1 protein predicts survival of
CRC patients
To ﬁnally assess the clinical relevance of DOK1 protein expression in
situ, we stained tissue microarrays (TMAs) by immunohistochemistry
(IHC) comprising a large cohort of CRC patients (n= 1648). Anti-C Ab
(ab8112) (Siouda et al., 2014) was used because it detected the most
abundant DOK1 variants (FL p62 and p44) in human tissues. DOK1 pro-
tein was present in the nucleus and cytoplasm of epithelial and stromal
cells in the normal colon mucosa (e.g. enterocytes and leukocytes) and
in tumor cells. Apical perinuclear accumulation of DOK1 protein was
also observed (Fig. 7A).
Frequency and intensity of DOK1 stainingwere correlated to clinico-
pathological factors. The overall DOK1 positivity score in tumor cells
was reduced (*p b 0.05; Fisher exact tests) with increasing tumor
stage (UICC) and the pTNM-categories local tumor growth (T), nodal
spread (N) and tumor grade (G); in stroma cells with T-, N- and M-cat-
egories and UICC stage (S3, Table S3). There was no association with
age, gender or anatomical localization of the tumor. Loss of DOK1 in
tumor cells (n = 1492 cases) predicted poor overall (OS) and tumor-
speciﬁc (TSS) survival (5 and 10-year OS [TSS]: DOK1 negative 53.7
and 44.3 [63.8 and 59.2] vs. 62.0 and 54.1 [70.8 and 67.4] DOK1 positive;
*p= 0.001 [0.003] log-rank test). Importantly, expression of cytoplas-
mic DOK1 correlated with improved prognosis (52.1 and 42.5 [62.2
and 57.3] vs. 61.1 and 53.3 [70.0 and 66.7]; *p= 0.001 [0.005]). In con-
trast, nuclear localization of DOK1 predicted poor outcome (59.4 and
50.9 [68.4 and 64.3] vs. 38.3 and 29.1 [51.1 and 49.6]; *p = 0.000
[0.011]). Similar results were obtained for tumor and stroma (Fig. 7B,
Table S4).
Separate analysis of survival for patient subgroups according to their
metastatic status (S4, Table S5) revealed that DOK1 expression was
prognostic in M0 but not in M1 cases. M1 was deﬁned by metastasis
to distant organs beyond regional lymph nodes. Similar resultswere ob-
tained forUICC stages (S5, Table S6), indicative of a prognostic relevance
for DOK1 in early stages of non-metastatic CRC. Cox regression was car-
ried out on all parameters with p b 0.1 in univariate survival analysis
(Metzger et al., 2016). Seven independent prognostic parameters
remained in the model after applying backward logistic regression, in-
cluding: gender, age, nodal spread (N), invasion to lymphatic vessels
(L), invasion to veins (V), tumor stage (UICC) and cytoplasmic DOK1 ex-
pression [hazard ratio (HR) = 0.809 (0.687–0.953); *p=0.011] (Table
S7). Clinical correlates were conﬁrmed in a smaller cohort of CRC pa-
tients (n= 40) and normal colon (n= 8) tissue specimens with anti-
N Ab (A3) which detected the predominant DOK1 variant (p37) in
transformed human cell lines (S6, Table S8).
In sum, loss of DOK1 protein expressionwas a frequent event in CRC
and conferred poor clinical outcome. Importantly, patients with gain of
nuclear DOK1 suffered from a worse prognosis.
3.9. Genomic alterations of DOK1 are rare events in CRC
To elucidate whether the observed changes in DOK1 protein are as-
sociated with DOK1 gene alterations, in silico mining of CRC patients'
data was done using the cBioportal of Cancer Genomics (Cerami et al.,
2012; Gao et al., 2013). DOK1 gene alterations were found in 3% of the
cases (n = 628; TCGA_Provisional (Network, 2012)) and in 4% of
human cancer cell lines (n = 1019; CCLE), mainly due to changes in
transcript levels, and the somatic mutation rate was low (b 0.3%). Over-
all alteration rates were b 10% in 86 cancer studies from N 15 tumor en-
tities. To see if DOK1 gene alterations correlate with patient survival,
information was retrieved for a 9-gene signature covering the RAS-sig-
naling pathway (EGFR, KRAS, NRAS, BRAF, MEK1, ERK2, CAV1, PPARG,
DOK1) (S7). Within this cooperative network, the latter 3 genes were
RAS-pathway inhibitors (“tumor suppressors”) (Ogino et al., 2009;
Burgermeister et al., 2011), the ﬁrst 6 genes oncogenic drivers (Misale
et al., 2012; Network, 2012). Median month overall (57.19 vs. 99.93;log-rank test p = 0.176; n = 545) and disease-free (63.37 vs. N 140;
log-rank test *p= 0.044; n= 531) survival was lower in CRC patients
with than without alterations in the query genes. In contrast to CAV1
(*p = 0.00714), the contribution of DOK1 gene alterations to survival
was not signiﬁcant.
RT-qPCR analyses (S8) on frozen CRC tissue samples (n= 10) from
matched normal colon (NC), primary tumor (TU) and liver metastases
(M) (stage IV) failed to revealed differences in DOK1mRNA expression,
neither between cases with good prognosis (no post-operative disease
recurrence, n = 13) vs. disease relapse (distant metastasis, n = 13)
nor in stage II (n = 26) and IV (n = 10) tumors regarding KRAS and
BRAFmutations. In contrast to down-regulation of PPARG (Ogino et al.,
2009) and CAV1 mRNAs, DOK1 mRNA was maintained in tumors and
metastases, proposing a functional role for DOK1 in CRC progression.
RT-qPCRs using primer pairs against the N- and the C-terminal part
(Burgermeister et al., 2011) of the FL DOK1 cDNA in human cell lines
(S8) evinced that the complete mRNA was present. CRC cell lines had
even higher levels of DOK1mRNA than NC tissue, suggesting a residual
function for DOK1 in malignant cells. Dok1mRNA was also detected in
primary enterocytes isolated from the intestines of C57BL6J mice (S8),
conﬁrming results in murine CRC (Friedrich et al., 2013).
Thus, subcellular patterns of DOK1 protein expression but not
changes in DOK1mRNA were associated with clinical factors in human
CRC. Conclusively, we could show that subcellular compartmentaliza-
tion of DOK1 contributes to progression of CRC and predicts patients'
survival (see model at a glance in Fig. 8). Speciﬁcally, cytoplasmic
DOK1 protein expressionwas an independent positive prognostic factor
for non-metastatic CRC.
4. Discussion
In the present study, we describe a role for compartmentalization of
DOK1 as a predictor of patient's survival in CRC.We characterized DOK1
as a regulator of transcription in contrast to signaling inhibition at the
plasma membrane. Consistent with reports from leukemias (Lee et al.,
2004, 2007), we had previously identiﬁed a p37–44 DOK1 variant in
human GC cells corresponding to the N-terminal part of FL p62 DOK1
(Burgermeister et al., 2011). We now demonstrate that human CRC
cells retain truncated DOK1 variants as well, pointing at a more general
principle. This held also true for transformed tissues from human and
mice in vivo, consistent with a frequent loss of DOK1 in other cancer
types (Berger et al., 2010; Balassiano et al., 2011; Saulnier et al., 2012).
The hitherto unknown functions of small DOK1 variants in cancer
cells were explored using expression plasmids for p44 DC (Kobayashi
et al., 2009) and p33 DN (Lee et al., 2004, 2007) which covered the C-
and N-terminal domains of FL p62 DOK1 (Songyang et al., 2001) (see
model in Fig. 1C). Endogenous p37 and p33 DN were located in the nu-
cleus, while FL p62 DOK1 and p44 DC were conﬁned to the perinuclear
area of the cytoplasm and at membranes colocalizing with the endo-
plasmic reticulum (ER). (Lee et al., 2004, 2007) presented leukemia pa-
tients with C-terminally truncated DOK1BCCL13 (p33–35)mutants in the
nucleus due to a frame shift that introduced a NLS and a premature stop
codon. Thus, cancer cells seem to retain nuclear (C-terminally truncat-
ed) (Lee et al., 2004, 2007) and cytoplasmic (N-terminally truncated)
(Kobayashi et al., 2009) DOK1 isoforms.
Thosemay be potentially defective variants that remain upon trans-
formation and loss of FL p62 DOK1 as a functional tumor suppressor
(Berger et al., 2010; Balassiano et al., 2011; Saulnier et al., 2012).
Our functional studies assigned the regions for PPARγ activation and
growth inhibition to the C-terminal part of DOK1, whereas the N-termi-
nal part of DOK1 was required for inhibition of the c-FOS promoter. The
DN and DC truncation variants were both sufﬁcient for interaction with
PPARγ provided they had a functional PTBdomain. Notably, mutation of
the PTB arginine residues (R207–223) (Zhang et al., 2004; Uhlik et al.,
2005; Oxley et al., 2008) in DOK1 and the MAPK-phosphorylation site
(S84) in PPARγ1 abolished the interaction. The 83ASPPYYSEKT92 site
Fig. 8. Signaling model at a glance. In cells with FL p62 DOK1 at the membrane or cytoplasmic p44 DCmutant, oncogenic signaling of many target proteins is inhibited (such as RTK, CTK,
SMAD, RAS, ELK1 e.a.) leading to reduction of SRE transcription (whichdrives cells into G1-S phase) and activation of PPRE transcription (whichdampens cell proliferation), two exemplary
read-outs used in the present study. PPARγ-agonist (star) further augments PPARγ-mediated growth inhibition, resulting in a good prognosis for patients' survival.Mechanistically, DOK1
may act as a “co-chaperone” for ligand-dependent nuclear translocation of PPARγ across the ER and nuclear pores. In tumor cells with loss of FL p62 DOK1 or accumulation of nuclear p33
DN mutant, oncogenic signaling (depicted here exemplary for the RAS-ERK1/2-ELK1-SRF pathway) is unimpeded leading to enhanced SRE and reduced PPRE transcription, resulting in
tumor cell proliferation and a poor prognosis. Mechanistically, MEK1 and ERK1/2 inhibit nuclear translocation of PPARγ by promoting its export to the cytoplasm and inactivation by
phosphorylation. Legend: red = active oncogene; blue black = active tumor suppressor; grey = inactive protein.
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serines by CDK5 (Choi et al., 2010) or CKII (von Knethen et al., 2010)
and resembles the NPXY (Uhlik et al., 2005) motif bound by PTB do-
mains also in an unphosphorylated state. Mutation of the leucine-rich
NES in DOK1 348LLKAKLTDP KEDPIYDEPEG367 (Niu et al., 2006),
which interacts with the zinc-ﬁnger “hakai tyrosine-binding domain”
(HYB) of the E3 ligase hakai (Mukherjee et al., 2012) and is phosphory-
lated by SRC (Songyang et al., 2001), together with deletion of the Dbox
motif 149DLNCRIHKKSRN160 (Zechel et al., 1994) in the second zinc-
ﬁnger of the PPARγ1 DBD also prevented complex formation (S2).
Both PPARγmutations accelerated cell growth, conﬁrming their defect
to interact and cooperate with DOK1.
FL p62 DOK1 and DC activated PPARγwithout being translocated to
the nucleus, whereas DN acted as a “nuclear trapping” mutant for
PPARγ. This pattern (Table S2) was consistent with the presence or ab-
sence of N-terminal NLS and C-terminal NES motifs in the DOK1 mu-
tants: FL (NLS+, NES+) and DC (NLS−, NES+) were exported to the
cytoplasm via their NES. DN (NLS+, NES−) was conﬁned to the nucleus
via a predicted NLS, as described for DOK7 (Hamuro et al., 2008). Thus,
DOK1 may act as a “co-chaperone” that brings PPARγ into proximity of
the nuclear envelope which is continuous with the ER. PPARs as mem-
bers of the nuclear receptor superfamily harbour at least one NLS in
the DBD (Kumar et al., 2006; Iwamoto et al., 2011) and are transported
across the nuclear pores by the default RAN GTPase-importin system.
DOK1 may thus rather facilitate the release of PPARγ from cytosolicsequestors (as shown for CAV1 or MEK1) (von Knethen et al., 2010;
Burgermeister et al., 2011) (S9) than acting as a speciﬁc nuclear import
shuttle for PPARγ. Mechanistically, DOK1 (alike MEK1) may also con-
tribute to recycling of PPARγ back to the cytosol for reloading with
ligand.
Nonetheless, DOK1 interacts with other transcription factors such as
SMAD3 and 4 (Yamakawa et al., 2002), and impacts on multiple signal-
ing pathways including JAK-STAT and NFκB relevant for proliferation,
apoptosis and inﬂammation (Downer et al., 2013; Nold-Petry et al.,
2015). Our data conﬁrmed (Yoshida et al., 2000) that DOK1 inhibits
the c-FOS promoter, amechanismwhich involves serum response factor
(SRF) and ternary complex factors (like ELK1) as shown for DOK4
(Baldwin et al., 2007). Thus, the causal link between DOK1 and RAS-sig-
naling in CRC remains unproven and is expected to involve higher com-
plexity than studied here exemplarily for PPARγ.
Taken together, our data propose that inhibition of signaling by
DOK1 is separated from its effect on transcription by the following
mechanisms: (i) across cell compartments and (ii) via different protein
variants (domains). Thereby, DOK1may switch frommembrane-bound
towards soluble cytosolic-nuclear targets. This alternative route shall
come into place in cases where failure to inhibit plasma membrane-
bound targets is common, e.g. due to constitutive RTK-RAS-signaling
upon mutation or ampliﬁcation events in cancers. This ﬂexibility of
DOK1 effector proﬁles may be part of a cellular defense response to ex-
ploit the remaining “downstream” tumor suppressive potential of DOK1
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family forms homo- and heterodimers (Mashima et al., 2009). Residual
small DOK1 variants in cancer cells may hijack this escape mechanism
to interfere with tumor growth even upon loss of FL p62 DOK1.
In the context of translational relevance of our study, we showed
that overexpression of DOK1 reduced, whereas knock-down of DOK1
enhanced cell proliferation, consistent with a decrease of DOK1 protein
expression along tumor progression in CRC patients. Genomic alter-
ations in a 9-gene signature covering the RAS-pathway correlated
with poor survival in CRC patients. There was no association of DOK1
mRNA with disease recurrence or KRAS-BRAF mutations, suggesting
that DOK1 still plays a role in established tumors. In line with this hy-
pothesis, we demonstrated that subcellular compartmentalization of
DOK1 protein is predictive for CRC patient's survival. These ﬁndings
may have implications for therapy. Expression of DOK1mRNA and pro-
tein can be up-regulated by PPARγ-agonists (Hosooka et al., 2008;
Burgermeister et al., 2011) (S10), and pharmacological induction of
Pparγ-Dok1-Cav1 genes made RAS drugable in a preclinical model of
murine CRC (Friedrich et al., 2013). CRC patients with RAS mutations
and a subset of RAS-WT tumors do not respond to clinical therapies
against the EGF receptor (Misale et al., 2012). Since DOK1 addresses al-
ternative targets (e.g. transcription factors) downstreamofmultiple sig-
nalingpathways (includingRAS), itmaybe suitable for future treatment
strategies in human cancers.5. Conclusions
Our study demonstrated that forward translation of a cell-based sig-
naling model predicted subcellular compartmentalization of DOK1 in
patients. Cytoplasmic expression of DOK1 (conferred by C-terminal do-
mains) correlated with improved prognosis in non-metastatic CRC and
evoked growth inhibition in human cancer cells, whereas nuclear DOK1
(conferred by N-terminal domains) predicted poor survival andwas in-
active in cells. The subcellular localization of DOK1may therefore serve
as a possible future prognostic marker for CRC progression. DOK1–
PPARγ interaction and expression was increased by PPARγ-agonist.
Hence, RTK-RAS signaling may be indirectly drugable “from within the
cell” by the insulin sensitizer rosiglitazone (Avandia®), constituting a
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